Limor Avrahami

TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.

TL;DR: Inhibition of GSK-3 restores lysosomal acidification that in turn enables clearance of Aβ burdens and reactivation of mTOR, which facilitates amelioration in cognitive function and provides evidence that mTOR is a target activated by G SKS-3 but inhibited by impaired lysOSomal Acidification and elevation in amyloid precursor protein/Aβ loads.

TL;DR: This study shows that overexpression of GSK-3 isoforms activated mTORC1 and suppressed autophagy in MCF-7 human breast cancer cells as indicated by reduced beclin-1 levels and upregulation of sequestosome 1 (p62/SQSTM1).

TL;DR: A new type of GSK-3 inhibitor, L807mts, is described that acts through a substrate-to-inhibitor conversion mechanism that occurs within the catalytic site of the enzyme.